During the last session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s traded shares were 1.37 million, with the beta value of the company hitting 1.70. At the end of the trading day, the stock’s price was $2.70, reflecting an intraday loss of -4.93% or -$0.14. The 52-week high for the ZNTL share is $18.24, that puts it down -575.56 from that peak though still a striking -1.48% loss since the share price plummeted to a 52-week low of $2.74. The company’s market capitalization is $191.99M, and the average intraday trading volume over the past 10 days was 1.24 million shares, and the average trade volume was 1.83 million shares over the past three months.
Zentalis Pharmaceuticals Inc (ZNTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.11. ZNTL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Zentalis Pharmaceuticals Inc (ZNTL) registered a -4.93% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.93% in intraday trading to $2.70, hitting a weekly high. The stock’s 5-day price performance is -18.67%, and it has moved by -24.37% in 30 days. Based on these gigs, the overall price performance for the year is -83.12%. The short interest in Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is 7.66 million shares and it means that shorts have 2.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 73.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $55 respectively. As a result, ZNTL is trading at a discount of -1937.04% off the target high and -48.15% off the low.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Statistics show that Zentalis Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Zentalis Pharmaceuticals Inc (ZNTL) shares have gone down -76.13% during the last six months, with a year-to-date growth rate more than the industry average at 32.44% against 17.30.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -50.05%. While earnings are projected to return 32.96% in 2024.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Zentalis Pharmaceuticals Inc insiders own 3.48% of total outstanding shares while institutional holders control 105.67%, with the float percentage being 109.48%. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 200.0 institutions own stock in it. As of 2024-06-30, the company held over 13.96 million shares (or 19.6902% of all shares), a total value of $57.1 million in shares.
The next largest institutional holding, with 8.68 million shares, is of FMR LLC’s that is approximately 12.2383% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.49 million.
